

Review article

The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children

Rachel C Vreeman^{§,1,2,3}, Michael L Scanlon^{*,1,2}, Megan S McHenry^{*,1,2} and Winstone M Nyandiko^{*,2,3}

[§]**Corresponding author:** Rachel C Vreeman, Children's Health Services Research, Department of Pediatrics, Indiana University School of Medicine, 410 W. 10th Street, HITS Suite 1000, Indianapolis, IN 46202, USA. Tel: +1 317 278 0552. Fax: +1 317 278 0456. (rvreeman@iu.edu)

*These authors have contributed equally to this work.

Abstract

Introduction: As highly active antiretroviral therapy (HAART) transforms human immunodeficiency virus (HIV) into a manageable chronic disease, new challenges are emerging in treating children born with HIV, including a number of risks to their physical and psychological health due to HIV infection and its lifelong treatment.

Methods: We conducted a literature review to evaluate the evidence on the physical and psychological effects of perinatal HIV (PHIV+) infection and its treatment in the era of HAART, including major chronic comorbidities.

Results and discussion: Perinatally infected children face concerning levels of treatment failure and drug resistance, which may hamper their long-term treatment and result in more significant comorbidities. Physical complications from PHIV+ infection and treatment potentially affect all major organ systems. Although treatment with antiretroviral (ARV) therapy has reduced incidence of severe neurocognitive diseases like HIV encephalopathy, perinatally infected children may experience less severe neurocognitive complications related to HIV disease and ARV neurotoxicity. Major metabolic complications include dyslipidaemia and insulin resistance, complications that are associated with both HIV infection and several ARV agents and may significantly affect cardiovascular disease risk with age. Bone abnormalities, particularly amongst children treated with tenofovir, are a concern for perinatally infected children who may be at higher risk for bone fractures and osteoporosis. In many studies, rates of anaemia are significantly higher for HIV-infected children. Renal failure is a significant complication and cause of death amongst perinatally infected children, while new data on sexual and reproductive health suggest that sexually transmitted infections and birth complications may be additional concerns for perinatally infected children in adolescence. Finally, perinatally infected children may face psychological challenges, including higher rates of mental health and behavioural disorders. Existing studies have significant methodological limitations, including small sample sizes, inappropriate control groups and heterogeneous definitions, to name a few.

Conclusions: Success in treating perinatally HIV-infected children and better understanding of the physical and psychological implications of lifelong HIV infection require that we address a new set of challenges for children. A better understanding of these challenges will guide care providers, researchers and policymakers towards more effective HIV care management for perinatally infected children and their transition to adulthood.

Keywords: children; adolescents; perinatal HIV infection; development; HIV comorbidities; psychological complications.

Received 27 April 2015; Revised 25 July 2015; Accepted 2 September 2015; Published 2 December 2015

Copyright: © 2015 Vreeman RC et al; licensee International AIDS Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported (CC BY 3.0) License (<http://creativecommons.org/licenses/by/3.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

An estimated 3.2 million children currently live with human immunodeficiency virus (HIV) [1]. Children with perinatal HIV infection (PHIV+) in the era of highly active antiretroviral therapy (HAART) have significantly improved odds of survival compared to the pre-HAART era [2] and are living into adolescence and adulthood in unprecedented numbers [3,4]. In the United States, mortality amongst HIV-infected children declined from 7.2 per 100 child-years in 1994 to 0.6 per 100 child-years in 2006, a more than 90% reduction [5]. Similar achievements have been made in Europe [6]. In these resource-rich settings, PHIV+ live longer, and fewer die of opportunistic infections [7], but PHIV+ still face significantly higher odds of morbidity and mortality compared to their

uninfected peers [8,9]. Overall, it is estimated that HIV-infected children have mortality rates 30 times higher than uninfected children of similar age in the United States [10]. Although deaths from opportunistic infections have decreased significantly, deaths from end-stage, acquired immunodeficiency syndrome (AIDS), sepsis and renal failure are now more common [10]. And as HIV infection transforms from a terminal illness to a chronic disease, new comorbidities emerge, including metabolic disorders and cardiovascular and kidney diseases [11]. These comorbidities represent significant challenges to the long-term treatment and survival of PHIV+.

More than 90% of the world's PHIV+ live in resource-limited settings (RLS) such as sub-Saharan Africa (SSA), where

less than a quarter of infected children currently receive HAART [12] and HIV/AIDS is still a leading cause of childhood and adolescent mortality [13]. In 2014, UNAIDS and partner stakeholders released ambitious new targets for the scale up of HIV testing and treatment, known as “90-90-90.” The aim is that by 2020, 90% of HIV-infected individuals will know their HIV status, 90% of diagnosed HIV-infected individuals will receive HAART, and 90% of HIV-infected individuals on HAART will be virally suppressed [14]. In addition, the 2013 World Health Organization (WHO) Consolidated ARV Guidelines recommend HAART for all PHIV+ under five years of age regardless of clinical or immunological stage [15]. The push towards these targets means that hundreds of thousands of PHIV+ will initiate life-long HAART over the next decade.

Although the majority of these children will be living in RLS, the experiences of PHIV+ in resource-rich settings, who have been treated with HAART for many more years, offer an important window into the long-term impact of perinatal infection and lifelong treatment across all settings. The objective of this review is to summarize and evaluate current evidence on the physical and psychological effects of PHIV+ infection and its treatment in the HAART era, including major chronic comorbidities. Insights will be offered on persistent and emerging challenges in the field of PHIV+ and future directions for research. Although much of the literature in this field comes from resource-rich settings, we will attempt to give appropriate attention to issues affecting PHIV+ in SSA.

Methods

We conducted an extensive, literature review on the physical and psychological effects of PHIV+ infection and its treatment in the HAART era, including major chronic comorbidities. Our methodology for this review was guided by Grant and Booth [16] and their definition of a “literature review.” We searched major scientific literature databases (e.g. PubMed, EMBASE and MEDLINE) between 1 February 2015 and 1 June 2015, and we used relevant keywords to guide searches for appropriate sources. In this review, we aim to present findings from major, landmark studies, as well as from meta-analyses, systematic reviews and expert commentaries, to evaluate the current state of knowledge and to identify research gaps on the physical and psychological effects of PHIV+ infection. Where appropriate, we include statistics such as odds ratios (OR), hazard ratios (HR) and confidence intervals (CI), amongst other statistics. To facilitate our objective, we organized the Results and Discussion section in the following way: first, we review the general virologic and treatment outcomes of perinatally infected children, then discuss physical effects using an organ systems perspective (birth and growth outcomes, neurological, cardiovascular, gastrointestinal, renal, haematological, metabolic, musculoskeletal and reproductive), and end with a review of psychological effects.

Results and discussion

Viral and treatment outcomes

Studies from North America and Europe suggest that PHIV+ have lower probability of achieving both viral suppression and long-term treatment success compared to adults [17,18].

Data from RLS are limited but suggest more similar outcomes for children and adults. A recent, systematic review compiled data from 30 studies on treatment failure amongst 3241 children <18 years of age on first-line HAART in RLS [19]. In seven studies using a definition of treatment failure as a viral load (VL) >400 copies/mL, a median of 36% of children (range 13 to 71%) had failed first-line HAART [19]. Slightly better outcomes were reported in a systematic review of 89 studies including 9794 adult patients from SSA, in which a median of 28% had failed after one year [20]. Authors of both systematic reviews cited major challenges in comparing data across studies due to heterogeneous study designs, definitions, methods and length of follow-up.

Inadequate viral suppression can lead to the development of drug resistance in adults [21–24] and in children [25,26]. Drug resistance amongst PHIV+, who need lifelong therapy beginning at birth, is particularly concerning for their long-term outcomes. The challenges of lack of viral suppression and developing drug resistance are magnified for PHIV+ in RLS, where they often have limited access to adequate viral monitoring and to second- and third-line HAART regimens. Aggregated data reveal concerning rates of ARV resistance amongst PHIV+. Sigaloff *et al.* [19] reviewed data from 30 studies including 2258 HIV-infected children who had failed their first-line HAART regimen and calculated that a pooled proportion of 90% of children had a resistance-associated mutation (95% CI 88 to 93%). In subgroup analyses of children who failed treatment less than one year after HAART initiation, 76% (95% CI 69 to 83%) had at least one resistance-associated mutation [19]. The authors did not investigate differences in treatment failure or drug resistance by route of infection (perinatal versus other), presumably because few studies reported this information.

PHIV+ may be at higher risk for treatment failure and drug resistance for several reasons. First, PHIV+ may be exposed to HAART *in utero* or during breastfeeding for (unsuccessful) prevention of mother-to-child transmission (PMTCT) [27]. In the United States, the widespread use of HAART for PMTCT has reduced mother-to-child transmission to around 2% [28]. Despite its effectiveness, access, retention and adherence to PMTCT are not adequate and may be especially difficult in resource-poor settings [29,30]. Second, the risk of drug resistance is higher for many older PHIV+ with complicated treatment histories of monotherapy or dual therapy before the advent of HAART [31]. Third, studies show that significant proportions of PHIV+ have less than optimal therapeutic drug levels [32–35]. Subtherapeutic drug levels may be too low for viral suppression, yet sufficient to exert selection pressure that facilitates resistance mutation evolution [36–40]. Although non-adherence is a significant cause of subtherapeutic drug levels (see next section), even PHIV+ with high levels of adherence can fail treatment and develop drug resistance, particularly with longer treatment durations [41]. Conversely, supratherapeutic drug concentrations can also be problematic and can lead to drug toxicities, more severe side effects and non-adherence. Limited paediatric formulations, variable pharmacokinetics (PK) and dosing data, and frequent changes in dosing across the developmental course likely contribute to inadequate treatment of PHIV+, but more

data are needed to address these challenges [42,43]. Finally, PHIV+ are a unique cohort; they acquire HIV before the maturation of their immune and organ systems and grow up with early and lifelong exposure to HAART [44].

Closely linked to the treatment outcomes for PHIV+ is the issue of medication adherence. Adherence to HAART is the critical behaviour underlying many of the long-term outcomes for children and adolescents with HIV. Systematic reviews of PHIV+ adherence to HAART have reported widely variable adherence estimates, likely due to heterogeneous measurement techniques [43,45]. Three studies (one in the United States and two in SSA) using electronic dose monitors, typically considered the gold standard measure [46–48], showed high rates of median adherence amongst PHIV+ (81, 95 and 96% of doses taken) [46,49,50]. Although high median rates of adherence are encouraging, they may not tell the whole story; patterns of adherence behaviour may critically shape outcomes. In the study from Kenya, only 68% of 191 PHIV+ achieved at least 90% adherence and they had a median of three treatment interruptions of greater than 48 hours over six months [50]. Another study in Kenya amongst a cohort of 21 PHIV+, established PK parameters for nevirapine (NVP) and used electronic dose monitors to calculate that almost half of the children spent more than 10% of time below the minimum effective drug concentration over four months of follow-up [51]. Although we know that non-adherence and clinical outcomes such as treatment failure are strongly associated [52,53], we lack data to characterize fully the relationship between adherence and drug resistance, particularly for PHIV+ in SSA. The risks of resistance resulting from non-adherence may vary based on regimen class, specific adherence patterns (e.g. treatment interruptions versus sporadic missed doses) and host genomics, in addition to the paediatric-specific factors just described [54]. Moreover, there are few data to inform strategies to improve and sustain high levels of adherence and prevent drug resistance in PHIV+ [43,55]. Studies do suggest that adherence and viral suppression decrease as PHIV+ transition into adolescence, highlighting the need for adherence interventions during this time [56–58].

It is in the context of these unique viral and treatment challenges that we must consider the impact of the physical and psychological effects of lifelong HIV infection, HAART treatment and comorbidities over the developmental course. Emerging data in these areas will be the focus of the remainder of this review.

Birth outcomes

Fostering the growth of PHIV+ remains a major challenge throughout the developmental spectrum, from the prenatal to the adolescent phase. Although stillbirth, preterm birth and low birthweight have declined significantly in the era of PMTCT and HAART in resource-rich settings [59], several studies found increased risk of preterm delivery with maternal HAART use (versus mono or dual therapy for PMTCT), especially with protease inhibitor (PI)-containing regimens [60–64]. Data from SSA in this area are sparse [65]. A meta-analysis of studies conducted before 2007 found no overall link between HAART use during pregnancy and increased risk for preterm

birth, but reported a significant association between PI-containing regimens and preterm birth versus non-PI containing regimens (OR 1.4, 95% CI 1.1 to 1.7), as well as maternal HAART started before pregnancy or in the first trimester versus later in pregnancy (OR 1.7, 95% CI 1.1 to 2.7) [66]. More recent results from a study amongst a large, well defined national cohort, the French Perinatal Cohort, found that ritonavir-boosted PI regimens were associated with an increased probability of preterm birth compared with non-boosted PI regimens (adjusted HR 2.0) when controlling for factors known to be associated with preterm delivery [67]. Preterm infants are at a significantly higher risk for a range of complications, including respiratory problems, infections, disability and mortality, and these risks may be compounded for PHIV+ [68]. More data are needed, particularly from SSA where the vast majority of HIV-positive women reside, health systems are less capable of caring for preterm infants, and where preterm delivery rates are the highest in the world [69].

Growth and development

Throughout childhood, PHIV+ tend to have shorter stature, lower bodyweight and delayed entrance into puberty compared to uninfected children, even in the absence of overt AIDS or wasting [70]. This abnormal growth is associated with a wide set of factors, including viraemia, symptomatic HIV infection, malabsorption, inflammation, mitochondrial toxicity, psychosocial factors, micronutrient deficiency, abnormal nitrogen balance, and impaired growth hormone secretion or action [70]. A study using two large US longitudinal cohorts between 2000 and 2012 found that the timing of pubertal onset (Tanner stage ≥ 2) was significantly later for 2086 PHIV+ compared to 453 HIV-exposed uninfected children [71]. Amongst PHIV+, the study also found that higher VL and lower CD4% were associated with more delayed pubertal onset, and that increased duration on HAART was associated with slightly more normal pubertal onset [71]. These data suggest that early access to HAART leads to more normal growth patterns for PHIV+, but there are few data from SSA where children are more likely to be malnourished and suffer from other diseases that are associated with poor growth [72].

Neurological outcomes

The incidence of severe, AIDS-defining neurocognitive diseases, such as HIV encephalopathy, has significantly declined in the HAART era [73,74]. Amongst 2398 PHIV+ in the US-based Pediatric AIDS Clinical Trials Group (PACTG) 219/219C cohorts followed from 1993 to 2007, incidence of HIV encephalopathy decreased 10-fold beginning in 1996 (corresponding to the rollout of HAART), with stable incidence rates since 2002 at around two cases per 1000 person-years [75].

Nonetheless, PHIV+ on HAART may experience less severe neurocognitive complications, including deficits in general cognition, language and speech, gross motor, and fine motor functioning, which can substantially affect their quality of life, social relationships, school achievements and risk behaviours [76–81]. Several potential mechanisms for cognitive impairment in PHIV+ on HAART have been proposed, including (1) irreversible pre-HAART neuronal injury; (2) neuronal injury from inflammatory responses and neurotoxic viral proteins; (3) poor central nervous system (CNS) penetration of ARVs

resulting in ongoing CNS viral replication and (4) neurotoxic effects of ARVs [82–86].

A number of studies reported that HIV-infected children treated with HAART had lower neurocognitive scores, high rates of motor deficits and delayed development compared to uninfected peers [87–95]; however, many of these studies were hampered by small sample sizes, lack of adequate control groups and lack of control for disease severity [86]. Several recent studies provided evidence for the protective effects of early HAART and viral suppression on neurodevelopment in PHIV+ [96,97]. A prospective study amongst 90 PHIV+ South African children randomized to receive early versus deferred HAART found significantly better neurodevelopment outcomes at 11 months of age as measured by the Griffiths Mental Development Scales in the early treatment group, who had a mean age of ART initiation at 8.4 weeks versus 31.4 weeks for the deferred treatment group [96]. Mental development scores from PHIV+ in the early treatment group were comparable with scores from HIV-uninfected (both exposed and unexposed) controls [96]. A study amongst 396 PHIV+ (mean age 9.6 years) in the United States found that early viral suppression (at five years of age or younger) was associated with higher cognitive scores on the Wechsler intelligence scales [97]. The study also found stronger associations in later birth cohorts when HAART use was more widespread, suggesting that HAART may improve neurocognitive outcomes independent of viral suppression [97]. In contrast, a study of 284 Thai and Cambodian PHIV+ aged 1 to 12 years in the PREDICT trial who were randomized to early or deferred HAART initiation reported no differences in neurodevelopmental scores between the two groups after 144 weeks, and found both early and deferred groups performed worse than uninfected controls [98,99]. However, the median age of HAART initiation was 6.4 years for the early group – significantly later than HAART initiation in the South Africa and US studies – which supports that neurological protective effects may be most significant in infancy and early childhood [98].

The potential effects of ARV-related neurotoxicity on neurodevelopment amongst PHIV+ are not clear and must be weighed against the benefits of CNS viral control. Cognitive impairment and decline in PHIV+ on HAART with good immunologic and systemic viral control [85] may point to a lack of CNS viral suppression due to poor drug CNS penetration, CNS-resistant virus, persistent immune activation or unknown factors [86]. Complicating this issue, ARVs that have high CNS penetration may better control HIV replication in cerebral spinal fluid that is associated with progressive HIV disease and neurocognitive deficits [100,101]. At the same time, ARVs with high CNS penetration may also increase the risks of ARV-related neurotoxicity. There are too few data amongst PHIV+ to assess the relationship between the level of CNS penetration by HAART agents and neurocognitive outcomes [74,75,97], and data amongst adults are conflicting [102–106].

A better understanding of the role of HIV infection and HAART on neurocognitive outcomes is needed to optimize treatment and to support the development of PHIV+ through adolescence and into adulthood. The field particularly lacks

data from PHIV+ in SSA and data on how HIV infection and HAART exposure *in utero* affect neurocognitive development, as well as how these effects might be mitigated. Although studies advocate for the protective effects of HAART early in infancy [96,97], which is consistent with current WHO guidelines [15], whether these benefits will persist through adolescence and adulthood remains to be seen. More data from well-designed, longitudinal studies are warranted, in combination with measurement instruments adapted for children in SSA settings. This should be a high-priority research area as access to PMTCT and HAART expands, particularly in SSA.

Cardiovascular system

The cardiovascular complications of HIV infection were noted early in the epidemic [107]. Current evidence suggests that PHIV+ may be at increased cardiac risk due to viral mechanisms [108], exposure to HAART for treatment or *in utero* for PMTCT or some combination [109]. Potential mechanisms of HIV-associated cardiomyopathy include direct infection of cardiac myocytes [107,110,111], increased production of certain cytokines within the myocardium [112–114] and nucleoside reverse transcriptase inhibitor (NRTI)-induced mitochondrial toxicity [115–117] that is most associated with zalcitabine, didanosine (ddI), stavudine (d4T) and zidovudine (AZT) [118–122]. The P2C2 study was the first major cohort study of PHIV+ to investigate cardiac complications and found high five-year cumulative incidence rates of depressed shortening fraction (28%), left ventricular end-diastolic dilation (22%), and heart failure or need for cardiac medications (29%); however, PHIV+ in this cohort had little exposure to modern HAART regimens [123,124].

More recent data suggest largely protective cardiac effects from HAART, especially early in life. In the largest prospective cohort study to date, 3035 PHIV+ enrolled in PACTG 219/219C were followed from 1993 to 2007 and showed that the use of HAART (versus no HAART) dramatically lowered incidence rates (by an average of 50%) of cardiomyopathy [125]. In subanalyses amongst HAART users, older age at HAART initiation, nadir CD4% below 15%, and initiating an AZT-containing regimen were independently associated with an increased risk of cardiomyopathy [125]. In another well-designed study, 70 PHIV+ from the earlier P2C2 study who had little exposure to HAART had significantly lower (i.e. worse) z-scores for left ventricular fractional shortening at around age 10 compared to 325 PHIV+ from the AMP cohort who had widespread use of HAART ($p < 0.05$) [126]. Longer ARV exposure and lower nadir CD4% were associated with lower mean left ventricular fractional shortening z-scores in PHIV+ from the P2C2 cohort but not from the AMP cohort, suggesting that cardiac damage was more significant for PHIV+ early in life who did not receive effective HAART [126].

The effects of HAART exposure *in utero* are unclear, as two major studies amongst ART-exposed uninfected infants revealed conflicting results [127,128]. The CHART-1 study found evidence that foetal exposure to HAART was associated with reduced left ventricular mass, left ventricular dimension and septal wall thickness [127], whereas the larger SMARTT study found low risk of overall cardiac anomalies and

no specific increase in anomalies with any individual ARV [128]. Studies in SSA are lacking and were mostly conducted before widespread use of HAART [129–131]. The long-term effects of HAART exposure on PHIV+ in adolescence and young adulthood are also unknown. A small study of 28 PHIV+ with a mean age of 18.0 years who had been on HAART for a mean of 14.6 years found that although standard echocardiographic measures were normal, there was evidence of high impaired strain and strain rate (which have been proposed as prognostic factors for long-term myocardial dysfunction [132]) compared to age-matched, uninfected, unexposed controls [133]. The clinical impact of these changes over time is not known.

Although cardiovascular complications have significantly declined in the HAART era, PHIV+ still may be at higher risk for cardiomyopathies. Further research is needed on the long-term myocardial function of PHIV+ and on optimizing HAART regimens to protect cardiac health and to effectively suppress HIV replication. Close monitoring of cardiovascular function for this population is warranted, as is surveillance for HIV-uninfected children exposed to HAART *in utero* – a population that will increase significantly in size with more access to PMTCT under the 90-90-90 target.

Gastrointestinal system

A prominent area of concern is the impact of HIV infection and its treatment on liver function for PHIV+, though there are few paediatric-specific data and long-term outcomes are mostly extrapolated from adult data [134]. PHIV+ tend to have HIV-associated elevated aspartate aminotransferase-to-platelet ratio indices, which may indicate liver fibrosis [135,136]. There are more data on the impact of HAART on liver function, which must be closely monitored in PHIV+. Almost all ARVs – in particular, atazanavir, ddI, indinavir and NVP – have the potential to cause hepatitis, hyperbilirubinaemia, liver toxicity and liver dysfunction [137]. In a small study of 26 PHIV+ on HAART aged 8 to 18 years, more than half had biological and/or radiological signs of hepatic impact, which was associated with older age, advanced disease stage and treatment with NRTI- and non-nucleoside analogue reverse transcriptase inhibitor (NNRTI)-containing regimens [138]. Regular monitoring of the liver function of PHIV+ is critical, which is now possible using various non-invasive procedures [138].

Co-infections can complicate treatment and increase the risks for liver damage, as is seen amongst HIV-infected adults with Hepatitis B virus (HBV) and Hepatitis C virus (HCV) co-infection [139]. There are comparatively few data on HBV and HCV co-infection amongst PHIV+, but a small number of studies suggest significant levels of chronic HBV and HCV co-infection [140–143]. Hepatitis co-infection requires specific treatment to reduce the risks of liver disease, hepatic fibrosis and cirrhosis in PHIV+ [144,145].

Renal system

Renal disease is a growing concern for PHIV+ [146], and now accounts for 5% of mortality amongst PHIV+ in the HAART era [10]. The risk of HIV-associated nephropathy (HIVAN) has declined significantly with the rollout of HAART [147], but there are chronic renal complications predicted by renal abnormalities that may be caused by long-term HIV infection

[148,149] and exacerbated by nephrotoxic ARVs [150]. This may be a particular concern with tenofovir disoproxil fumarate (TDF)-containing regimens in PHIV+, but study findings are not consistent [151–154]. The most common histopathological abnormality identified in renal biopsies in children with HIVAN is focal segmental glomerulosclerosis [155]. Host genomics play a significant role in the development of HIVAN, resulting in a fourfold increased risk for end-stage, kidney disease in African Americans in the United States [156,157]. High rates of renal disease amongst HIV-infected adults have been reported in SSA, along with evidence of a broader spectrum of histopathological lesions, but there are few data amongst PHIV+ [158]. A retrospective analysis of PHIV+ in the US-based PACTG 219/219C cohorts identified a variety of immune complex-mediated glomerulonephritides and HIVAN, with an incidence rate of chronic kidney disease of 2.79 events per 1000 person years in the 2003 to 2006 HAART era [159]. Other longitudinal cohort studies in the United States have found prevalence rates of nephrotic-range proteinuria between 8 and 11% amongst PHIV+ on HAART, with common risk factors of renal dysfunction including older age, uncontrolled viraemia, African-American race and use of TDF-containing regimens [160,161].

There are few data on survival outcomes amongst PHIV+ with end-stage kidney disease on maintenance dialysis in the HAART era. Two small studies amongst HIV-infected children with end-stage kidney disease on maintenance haemodialysis in the United States reported high mortality associated with cardiovascular disease, leading the authors to recommend routine echocardiography amongst HIV-infected children on dialysis [162,163]. Studies on kidney transplantation for HIV-infected individuals on HAART with end-stage kidney disease, once contraindicated in this population, show comparable three to five years survival rates to transplantation in uninfected individuals [164–166], but there are few data amongst children. More longitudinal data are needed to guide screening, prevention and treatment of renal diseases amongst an aging PHIV+ cohort, particularly as kidney diseases evolve from more acute conditions associated with advanced HIV disease to chronic diseases associated with long-term HIV infection and HAART exposure, as well as potential metabolic disorders. For PHIV+ in SSA and other RLS, interventions to prevent end-stage kidney disease are especially urgent as access to dialysis and transplantation are limited.

Haematological issues

A frequent complication of HIV infection is anaemia. HIV infection may alter cytokine and erythropoietin responses by decreasing erythropoiesis through apoptosis of erythroid precursors and infection of auxiliary cells [167,168]. A number of common co-infections in PHIV+, such as neoplasms [169] and bacterial and fungal infections [170–172] including mycobacterial infections (e.g. *Mycobacterium tuberculosis*) [173,174], also increase risks for anaemia. In addition, children with HIV are at greater risk for more severe malaria-related anaemia compared to uninfected children [175,176]. Treatment with HAART, especially with AZT-containing regimens, is associated with increased risk for anaemia in children

[177–179], including at birth for PHIV+ whose mothers were taking AZT for PMTCT [180,181]. A systematic review of 36 studies found that PHIV+ compared to uninfected children were at significantly higher odds of anaemia, with a calculated pooled random-effects OR of mild (haemoglobin <11 g/dL) and moderate (haemoglobin <9 g/dL) anaemia of 4.5 (95% CI 2.5 to 8.3) and 4.5 (95% CI 2.0 to 10.3), respectively, but there were few data on severe anaemia (haemoglobin <7 g/dL) [182]. Anaemia was commonly associated with HIV disease progression and mortality, and the use of HAART and treatment of secondary infections were protective, suggesting that as more PHIV+ access HAART and are able to switch regimens when AZT-associated anaemia is suspected, severe anaemia-related complications may be reduced in this population [182]. There is little evidence to support additional therapeutic interventions for anaemia amongst PHIV+, including interventions such as recombinant human erythropoietin and micronutrient supplementation, and more data are needed to evaluate these potential treatment options [183].

Metabolic impact

PHIV+ on HAART are at an increased risk for metabolic disorders [184–186]. Lipodystrophy syndrome (or “fat redistribution”) comprises both lipoatrophy (loss of subcutaneous fat from the face, limbs and buttocks) and lipohypertrophy (increase of central fat) and can occur independent of weight change and dyslipidaemia [187]. HAART-associated lipoatrophy and lipohypertrophy have different and multifactorial pathogenesises that may involve changes in genetic polymorphisms, lipid metabolism, and adipocyte and mitochondrial cell function [188,189]. Studies reported a prevalence of lipodystrophy for PHIV+ on HAART between 10 and 33% [190–196], but rates as high as 57% have been found in Europe [197,198] and 65% in Thailand [199]. Common risk factors for lipodystrophy include longer duration on HAART, older age (especially during puberty), more severe HIV disease, and regimens containing NRTIs (particularly d4T and AZT) and to a lesser degree PIs, which may act synergistically when used together [200,201].

Body fat changes may ultimately affect adherence to therapy amongst older children and adolescents because they affect body image and the social desire to fit in is a strong motivator of behaviour during adolescent development [202]. In addition, characteristic body fat changes associated with HIV treatment may be recognizable and elicit HIV-related stigma, leading to reduced quality of life and adherence to medications, particularly in settings like SSA where HIV/AIDS stigma is pervasive [203–205]. Proper management of HAART-associated fat redistribution is critical in supporting the long-term treatment of PHIV+, particularly in SSA where fewer regimen options are combined with higher risks of stigma.

Dyslipidaemia, including hypertriglyceridaemia (elevated triglyceride levels) and hypercholesterolaemia (elevated LDL-cholesterol levels), is another potential metabolic complication for PHIV+ on HAART [206]. Elucidating potential mechanisms of dyslipidaemia in the HAART era have focused on the impact of PIs on the inhibition of low-density lipoprotein receptor-related proteins [207]. Data are limited to mostly small studies from the United States and Europe,

where prevalence of hypertriglyceridaemia in PHIV+ on HAART ranges from 13 to 67% [186,190,192,208–211] and hypercholesterolaemia from 10 to 68% [186,190,192,208–212]. In the largest study to date amongst 2122 PHIV+ in the PACTG 219C cohort, the incidence rate for hypercholesterolaemia (total cholesterol \geq 220 mg/dL at two consecutive time points) was 3.4 cases per 100 person-years (95% CI 3.0 to 3.9) [213]. The most significant factors associated with the development of hypercholesterolaemia after adjusting for age were the use of PI-containing regimens and lower VL [213]. In a follow-up study of the 240 PHIV+ who developed hypercholesterolaemia, only 34% experienced resolution to normal cholesterol levels after two years [214]. Smaller studies have shown potential benefits from switching from a PI-based to NNRTI-based regimen but more data are needed to guide optimal treatment in PHIV+ [215–218]. Furthermore, although the first-line treatment for dyslipidaemia in children is to change the diet and increase physical exercise, there are not data on the efficacy of these strategies amongst PHIV+ on HAART, and there are not clear guidelines on lipid thresholds for the use of statins and other lipid-lowering medications in this population [219]. As more PHIV+ initiate lifelong HAART, access to lipid monitoring needs to be supported to reduce the potential for drug toxicity and long-term lipid disorders.

Insulin resistance is characterized by reduced insulin stimulation of glucose use by adipose tissue and muscles resulting in increased pancreatic insulin production, and is associated with obesity, dyslipidaemia, hypertension and type 2 diabetes in children [220]. Both PIs and NRTIs are associated with insulin resistance through inhibition of GLUT-4 transporters in myocytes and adipocytes, causing decreased uptake of glucose by these tissues [221,222]. HAART-associated body composition changes such as central obesity, resulting in fat deposition in muscle cells, may also contribute to insulin resistance [223], but data are inconclusive [224,225]. The prevalence of insulin resistance in PHIV+ varies widely, ranging from 7 to 52% [190,208,209,211,226,227]. In 2011, a study amongst a large cohort of 402 PHIV+ in the United States found insulin resistance in 15% of the cohort, which was most strongly associated with obesity but also with low CD4% and exposure to PIs [228]. The prevalence of other glucose metabolism disorders such as abnormal fasting glucose and impaired glucose tolerance amongst PHIV+ is typically much lower (below 7%), but studies are few and generally small [186,190,208,209,211,227]. As in the case of dyslipidaemia, treatment for insulin resistance includes diet and exercise, and in the case of suspected PI-caused insulin resistance, studies suggest improved insulin sensitivity with switches from a PI- to NNRTI-based regimen in PHIV+ [229–231].

PHIV+ are at an increased risk for a variety of metabolic complications, but there are few longitudinal data to assess incidence, risk factors and long-term outcomes of these metabolic disorders [232]. Existing studies are further complicated by small sample sizes, heterogeneous definitions and complex interrelations in aetiology and risk factors. Metabolic disorders are significant risk factors for the acceleration of cardiovascular disease amongst HIV-infected adults [233], but whether these complications lead to the same cardiovascular

risks in the ageing PHIV+ cohort remains to be seen [234]. As PHIV+ enter adolescence and young adulthood, optimizing treatment and reducing HIV-related and non-HIV-related risk factors for metabolic disorders are critical. Further data to guide prevention, monitoring and management of complications are urgently needed. PHIV+ in SSA may be at increased risk of poor diagnosis and management of complications due to lack of access to cardiac and metabolic monitoring tools.

Musculoskeletal system

PHIV+ may be at greater risk for lower bone mineral density (BMD) due to viral infection – by affecting BMD-related growth factors [235,236] – and due to HAART exposure [237,238], particularly TDF [239]. Recent studies amongst PHIV+ revealed conflicting results. Two studies reported significant BMD loss amongst children treated with TDF-containing salvage regimens, with one-third losing more than 6% BMD [240,241]. It is unclear how these findings were confounded by the children's uncontrolled HIV infection, although one study reported that two children who discontinued TDF had significant recovery of BMD at 96 weeks [240]. Other studies found no association between TDF-containing regimens and greater risk for lower BMD [218,242,243]. In the longest study to date, 26 PHIV+ on TDF-containing regimens were followed for 132 months and showed good viraemic control and no significant increase in serum creatinine [244].

The effects of TDF may vary by developmental stage; studies have reported that TDF-associated BMD loss is less significant in adolescents and adults compared to PHIV+ in pre- or early pubertal stages [245,246]. Younger children's BMD may be more affected because their skeletal growth requires higher bone turnover; however, the aetiology, long-term risks and consequences of lower BMD for PHIV+ are not known [247]. More data are needed to guide optimal treatment regimens and to identify potential long-term complications of decreased BMD amongst PHIV+, who may consequently be at higher risk for bone fractures and osteoporosis later in life.

Sexual and reproductive health

Studies show that having a sexually transmitted infection (STI) increases the risks for transmission and acquisition of HIV [248,249], but whether HIV-infected individuals on HAART with well-controlled HIV infection are at greater risk for STIs is less clear [250,251]. Several studies reported high rates of STIs amongst adolescents and young adults behaviourally infected with HIV [252–256], but there are fewer studies amongst PHIV+. A study of 638 PHIV+ adolescent women in the PACTG 219C cohort reported higher rates of condylomata acuminata, trichomoniasis and cervical abnormalities, including atypical cells, low-grade, squamous intraepithelial lesions and high-grade squamous intraepithelial lesions compared to matched, uninfected controls [257]. A cohort study of PHIV+ and behaviourally infected women in the United States found higher rates of pregnancy and premature births in both groups compared to the general population, with PHIV+ women significantly more likely to electively terminate the pregnancy compared to behaviourally infected women [258]. A recent retrospective cohort

study of 152 pregnancies in the United States reported that uninfected infants born to PHIV+ mothers were significantly shorter throughout the first year of life (after adjusting for confounding) compared to uninfected infants born to non-perinatally HIV-infected mothers [259], but the significance of these findings is unclear.

There is limited evidence to inform sexual and reproductive interventions amongst PHIV+. A recent systematic review found evidence that linking sexual and reproductive services with HIV/AIDS services resulted in improved outcomes for women, including HIV and STI incidence, condom use, contraceptive use and retention in care [260]. Effective service delivery methods for sexual and reproductive health care, in combination with adolescent care transitions [168, 261,262], must be investigated further as more PHIV+ enter adolescence and adulthood. In addition, the seldom-discussed issue of reproductive and sexual health for PHIV+ men will need to be addressed.

Psychological health

A number of studies reported high rates of mental and behavioural disorders amongst PHIV+ [92,263–265]. Studies in the United States found higher than expected rates of anxiety, depression, hyperactivity, learning, other behavioural problems amongst PHIV+ [92,263], as well as rates of psychiatric hospitalizations three times higher compared to the general paediatric population, most commonly for depression and behaviour disorders [264]. A review of eight studies on the prevalence of psychiatric disorders amongst HIV-infected children and youth (aged 4 to 21 years) using the *Diagnostic and Statistical Manual* (Fourth Edition; DSM-IV) found high rates of attention deficit/hyperactivity disorders (29%), anxiety (24%) and depression (25%); however, the authors noted the lack of control groups and small sample sizes as significant limitations [265]. Several reviews have similarly pointed to the methodological weaknesses in existing studies on psychosocial outcomes amongst PHIV+ and the complex interactions of genetic, social and environmental factors [266,267]. Indeed, in larger, more well-designed trials with appropriate control groups, studies reported less evidence for increased mental and behavioural disorders amongst PHIV+ in childhood or adolescence [263,268–270]. In a US study, the authors found that PHIV+ were no more likely to have psychiatric symptoms than age-matched HIV-exposed uninfected controls, but were significantly more likely to be diagnosed and to have received treatment for a psychiatric disorder, including receiving psychotropic medication [268].

There is scarce evidence in the existing literature on the specific role of HIV or HAART in affecting psychological outcomes [267]. Several studies reported that low cognitive functioning scores were associated with mental health disorders amongst PHIV+ [92,98,271], but the significance of this finding is not clear. Clinical disease markers such as AIDS defining illness [272,273], higher VL [272,274] and low CD4 [272,275] were associated with mental and behavioural disorders amongst PHIV+ in some studies, but not in others [263,276,277]. There are also few data on psychological outcomes amongst PHIV+ in RLS [278–280]. High rates of orphanhood amongst PHIV+, particularly in SSA, may be an

additional non-disease-related factor affecting mental and behavioural health [281–284]. Rigorous studies in settings such as SSA are hampered by a lack of rigorously evaluated and validated tools for assessing mental and behavioural disorders in paediatric populations [285]. As hundreds of thousands of PHIV+ transition into adolescence and adulthood, data are needed on the psychological challenges and targeted mental and behavioural interventions for PHIV+, which are critical to support their long-term chronic disease management [267].

Conclusions

The advent of HAART drastically changed the course of HIV and significantly decreased HIV-associated morbidity and mortality. Although HAART allows PHIV+ to survive and prosper well into adolescence and adulthood, PHIV+ still face many challenges related to their perinatal infection and lifelong treatment. This review identified major chronic complications and comorbidities affecting all major organ systems. As more PHIV+ access HAART and live longer over the next decades, data that improve the management and ultimately prevention of these complications over the course of the developmental spectrum are critical. For PHIV+ with HIV-related disabilities, rehabilitation interventions are necessary to support their development with a chronic condition, but there are few data in this area [286,287]. The transition of PHIV+ from paediatric into adolescent and adult care settings is another under-researched area with significant implications for the treatment of long-term complications and comorbidities in PHIV+.

Many studies included in this review were conducted in the United States and Europe. PHIV+ in resource-rich settings represent an important population for study as they are mostly older, have been treated with HAART for many more years, and often initiated treatment at earlier ages compared to PHIV+ in RLS. For these reasons, PHIV+ in resource-rich settings offer critical insight into long-term complications and comorbidities and interventions to improve treatment and clinical outcomes. In addition, well-established cohorts such as the PACTG 219/219C in the United States provide opportunities to conduct studies with relatively large sample sizes and close monitoring and follow-up of patients. These cohorts have been particularly useful in investigating complex effects on different organ systems from HIV infection, HAART treatment or a combination of both. On the other hand, we did identify a number of recent studies from SSA, which is encouraging given that the region is home to over 90% of PHIV+ in the world. Studies across regions, both resource-rich and resource-poor, had significant limitations, most often issues of sample size, appropriate control groups, length of follow-up, heterogeneous definitions and assessment methods, and unknown and complex interrelations in aetiology and risk factors. Across all areas of research identified in this review, more research is needed that uses improved methodologies to address limitations. Establishing well-characterized and closely followed cohorts of PHIV+ in SSA and other RLS (as well as HIV-uninfected exposed children) will be essential to answer important questions around lifelong infection and treatment [288].

The combined evidence from this review supports the protective effects of early HAART for PHIV+ against many infection-related complications across organ systems; however, there are unanswered questions around HAART toxicity and management of potential drug side effects, as well as persisting infectious impacts. As the WHO guidelines advocate for the treatment of all PHIV+ with HAART and we work towards the goals of “90-90-90,” hundreds of thousands of PHIV+ will be initiating early and lifelong HAART in the coming years. HIV care programmes, particularly those in SSA, will be tasked with huge challenges in expanding HAART treatment and managing chronic complications and comorbidities of PHIV+. Furthermore, persistent challenges in areas such as infant diagnosis [289,290] and retention in care [291], to name just a few, are additional barriers to effectively treating PHIV+ in these settings. Finally, HIV cannot be viewed as a problem only for the realm of infectious disease; effective healthcare systems for the millions of youth needing HIV treatment will incorporate a holistic approach to the management of children and families’ physical, mental, emotional, behavioural and social needs across the developmental course.

Authors’ affiliations

¹Children’s Health Services Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA; ²Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya; ³Department of Child Health and Paediatrics, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya

Competing interests

The authors of this manuscript have no competing interests to report.

Authors’ contributions

RCV led the design and writing of the manuscript. MLS and MSM contributed significantly to the literature review and writing of the manuscript. WMN contributed significantly to the design and revision of the manuscript. All authors have read and approved the final version.

Disclaimer

The views expressed in this article are those of the authors and do not necessarily represent the view of the Indiana University School of Medicine or the Moi University School of Medicine.

Acknowledgements

The entirety of this work was completed by the authorship team. No acknowledgements are required.

References

1. World Health Organization. Global update on the health sector response to HIV, 2014. Geneva: WHO; 2014.
2. Lee GM, Gortmaker SL, McIntosh K, Hughes MD, Oleske JM, Pediatric AIDS Clinical Trials Group Protocol 219C Team. Quality of life for children and adolescents: impact of HIV infection and antiretroviral treatment. *Pediatrics*. 2006;117(2):273–83.
3. Delaney M. History of HAART – the true story of how effective multi-drug therapy was developed for treatment of HIV disease. *Retrovirology*. 2006; 3(Suppl 1):S6.
4. McConnell MS, Byers RH, Frederick T, Peters VB, Dominguez KL, Sukalac T, et al. Trends in antiretroviral therapy use and survival rates for a large cohort of HIV-infected children and adolescents in the United States, 1989–2001. *J Acquir Immune Defic Syndr*. 2005;38(4):488–94.
5. Mofenson LM, Williams P, Brady MT, van Dyke RB, Dankner WM, Oleske JM. Trends in mortality in HIV-infected children in the United States – 1994–2006. XVII International AIDS Conference Mexico City; 2008 Aug 3–8; Mexico; 2008.
6. Judd A, Doerholt K, Tookey PA, Sharland M, Riordan A, Menson E, et al. Morbidity, mortality, and response to treatment by children in the

- United Kingdom and Ireland with perinatally acquired HIV infection during 1996–2006: planning for teenage and adult care. *Clin Infect Dis*. 2007;45(7):918–24.
7. Gona P, Van Dyke RB, Williams PL, Dankner WM, Chernoff MC, Nachman SA, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. *JAMA*. 2006;296(3):292–300.
8. Newell ML, Brahmbhatt H, Ghys PD. Child mortality and HIV infection in Africa: a review. *AIDS*. 2004;18(Suppl 2):S27–34.
9. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. *Lancet*. 2004;364(9441):1236–43.
10. Brady MT, Oleske JM, Williams PL, Elgie C, Mofenson LM, Dankner WM, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. *J Acquir Immune Defic Syndr*. 2010;53(1):86–94.
11. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. *Ann Rev Med*. 2010;61:169–85.
12. World Health Organization. Global HIV/AIDS response: epidemic update and health sector progress towards universal access – progress report 2011. Geneva: World Health Organization; 2011.
13. Patton GC, Coffey C, Sawyer SM, Viner RM, Haller DM, Bose K, et al. Global patterns of mortality in young people: a systematic analysis of population health data. *Lancet*. 2009;374(9693):881–92.
14. UNAIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS; 2014.
15. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treatment and preventing HIV infection. Geneva: WHO; 2013.
16. Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. *Health Info Libr J*. 2009;26(2):91–108.
17. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. *Lancet Infect Dis*. 2002;2(2):93–102.
18. Sabin CA, Smith CJ, d'Arminio Monforte A, Battegay M, Gabiano C, Galli L, et al. Response to combination antiretroviral therapy: variation by age. *AIDS*. 2008;22(12):1463–73.
19. Sigaloff KC, Calis JC, Geelen SP, van Vugt M, de Wit TF. HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. *Lancet Infect Dis*. 2011;11(10):769–79.
20. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. *Lancet Infect Dis*. 2010;10(3):155–66.
21. D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. *Ann Intern Med*. 1995;122(6):401–8.
22. Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. *AIDS*. 1999;13(2):F17–21.
23. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. *Ann Intern Med*. 1999;131(11):813–21.
24. Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. *Drugs*. 2012;72(9):e1–25.
25. Adje-Toure C, Hanson DL, Talla-Nzouso N, Borget MY, Kouadio LY, Tossou O, et al. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Cote d'Ivoire. *AIDS Res Hum Retrovir*. 2008;24(7):911–7.
26. Rojas Sanchez P, Holguin A. Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review. *J Antimicrob Chemother*. 2014;69(8):2032–42.
27. Moorthy A, Gupta A, Bhosale R, Tripathy S, Sastry J, Kulkarni S, et al. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. *PLoS One*. 2009;4(1):e4096.
28. Whitmore SK, Taylor AW, Espinoza L, Shouse RL, Lampe MA, Nesheim S. Correlates of mother-to-child transmission of HIV in the United States and Puerto Rico. *Pediatrics*. 2012;129(1):e74–81.
29. Ferguson L, Grant AD, Watson-Jones D, Kahawita T, Ong'ech JO, Ross DA. Linking women who test HIV-positive in pregnancy-related services to long-term HIV care and treatment services: a systematic review. *Trop Med Int Health*. 2012;17(5):564–80.
30. Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. *AIDS*. 2012;26(16):2039–52.
31. de Mulder M, Yebra G, Navas A, de Jose MI, Gurbindo MD, Gonzalez-Tome MI, et al. High drug resistance prevalence among vertically HIV-infected patients transferred from pediatric care to adult units in Spain. *PLoS One*. 2012;7(12):e52155.
32. Fraaij PL, van Kampen JJ, Burger DM, de Groot R. Pharmacokinetics of antiretroviral therapy in HIV-1-infected children. *Clin Pharmacokinet*. 2005;44(9):935–56.
33. Fraaij PL, Rakhmanina N, Burger DM, de Groot R. Therapeutic drug monitoring in children with HIV/AIDS. *Ther Drug Monit*. 2004;26(2):122–6.
34. Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, et al. High prevalence of subtherapeutic plasma concentrations of efavirenz in children. *J Acquir Immune Defic Syndr*. 2007;45(2):133–6.
35. Viljoen M, Gous H, Kruger HS, Riddick A, Meyers TM, Rheeders M. Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children. *AIDS Res Hum Retrovir*. 2010;26(6):613–9.
36. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. *AIDS*. 2001;15(9):1089–95.
37. de Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. *Clin Pharmacokinet*. 2003;42(6):599–605.
38. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. *AIDS*. 2001;15(1):71–5.
39. Csajka C, Marzolini C, Fattinger K, Decosterd LA, Fellay J, Telenti A, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. *Clin Pharmacol Ther*. 2003;73(1):20–30.
40. Stahle L, Moberg L, Svensson JO, Sonnerborg A. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. *Ther Drug Monit*. 2004;26(3):267–70.
41. Mullen J, Leech S, O'Shea S, Chrystie IL, Du Mont G, Ball C, et al. Antiretroviral drug resistance among HIV-1 infected children failing treatment. *J Med Virol*. 2002;68(3):299–304.
42. Menson EN, Walker AS, Sharland M, Wells C, Tudor-Williams G, Riordan FA, et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997–2005: cohort study. *BMJ*. 2006;332(7551):1183–7.
43. Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. *Pediatrics*. 2007;119(6):e1371–83.
44. Abuzaitoun OR, Hanson IC. Organ-specific manifestations of HIV disease in children. *Pediatr Clin North Am*. 2000;47(1):109–25.
45. Vreeman RC, Wiehe SE, Pearce EC, Nyandiko WM. A systematic review of pediatric adherence to antiretroviral therapy in low- and middle-income countries. *Pediatr Infect Dis J*. 2008;27(8):686–91.
46. Farley J, Hines S, Musk A, Ferrus S, Tepper V. Assessment of adherence to antiviral therapy in HIV-infected children using the Medication Event Monitoring System, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. *J Acquir Immune Defic Syndr*. 2003;33(2):211–8.
47. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. *Ann Intern Med*. 2001;134(10):968–77.
48. Deschamps AE, De Geest S, Vandamme AM, Bobbaers H, Peetermans WE, Van Wijngaerden E. Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. *AIDS Patient Care STDs*. 2008;22(9):735–43.
49. Haberer JE, Cook A, Walker AS, Ngambi M, Ferrier A, Mulenga V, et al. Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects. *PLoS One*. 2011;6(4):e18505.

50. Vreeman RC, Nyandiko WM, Liu H, Tu W, Scanlon ML, Slaven JE, et al. Measuring adherence to antiretroviral therapy in children and adolescents in western Kenya. *J Int AIDS Soc.* 2014;17:19227, doi: <http://dx.doi.org/10.7448/IAS.17.1.19227>
51. Vreeman RC, Nyandiko WM, Liechty EA, Busakhala N, Bartelink IH, Savic RM, et al. Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children. *J Acquir Immune Defic Syndr.* 2014;67(3):277–86.
52. Vignoles M, Barboni G, Agosti MR, Garcia M, Ferrari I, Mahler E, et al. High frequency of antiretroviral drug resistance and low percentage of drug detection in plasma in HIV-infected children with low virological failure AIDS 2008. XVII International AIDS Conference Mexico City; 2008 Aug 3–8; Mexico; 2008.
53. Gody JC, Charpentier C, Mbitikon O, Si-Mohamed A, LeGoff J, Gresenguet G, et al. High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. *J Acquir Immune Defic Syndr.* 2008;49(5):566–9.
54. Bangsberg DR, Kroetz DL, Deeks SG. Adherence–resistance relationships to combination HIV antiretroviral therapy. *Curr HIV/AIDS Rep.* 2007;4(2):65–72.
55. Reisner SL, Mimiaga MJ, Skeer M, Perkovich B, Johnson CV, Safren SA. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. *Top HIV Med.* 2009;17(1):14–25.
56. Murphy DA, Belzer M, Durako SJ, Sarr M, Wilson CM, Muenz LR, et al. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. *Arch Pediatr Adolesc Med.* 2005;159(8):764–70.
57. Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. *J Acquir Immune Defic Syndr.* 2009;51(1):65–71.
58. Williams PL, Storm D, Montepiedra G, Nichols S, Kammerer B, Sirois PA, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. *Pediatrics.* 2006;118(6):e1745–57.
59. Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG. Pediatric Spectrum of HIVDC. Declines in low birthweight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989–2004. *Pediatrics.* 2007;119(4):e900–6.
60. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? *J Infect Dis.* 2006;193(9):1195–201.
61. Ravizza M, Martinelli P, Bucci A, Fiore S, Alberico S, Tamburrini E, et al. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. *J Infect Dis.* 2007;195(6):913–14; author reply 6–7.
62. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. *AIDS.* 2004;18(17):2337–9.
63. Townsend C, Schulte J, Thorne C, Dominguez KI, Tookey PA, Cortina-Borja M, et al. Antiretroviral therapy and preterm delivery – a pooled analysis of data from the United States and Europe. *BJOG.* 2010;117(11):1399–410.
64. Townsend CL, Tookey PA, Newell ML, Cortina-Borja M. Antiretroviral therapy in pregnancy: balancing the risk of preterm delivery with prevention of mother-to-child HIV transmission. *Antivir Ther.* 2010;15(5):775–83.
65. Powis KM, Kitch D, Ogwu A, Hughes MD, Lockman S, Leidner J, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. *J Infect Dis.* 2011;204(4):506–14.
66. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. *AIDS.* 2007;21(5):607–15.
67. Sibiude J, Warszawski J, Tubiana R, Dollfus C, Faye A, Rouzioux C, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? *Clin Infect Dis.* 2012;54(9):1348–60.
68. Thorne C, Townsend CL. A new piece in the puzzle of antiretroviral therapy in pregnancy and preterm delivery risk. *Clin Infect Dis.* 2012;54(9):1361–3.
69. Beck S, Wojdyla D, Say L, Betran AP, Merialdi M, Requejo JH, et al. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. *Bull World Health Organ.* 2010;88(1):31–8.
70. Kim RJ, Rutstein RM. Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients. *Paediatr Drugs.* 2010;12(3):187–99.
71. Williams PL, Abzug MJ, Jacobson DL, Wang J, Van Dyke RB, Hazra R, et al. Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment. *AIDS.* 2013;27(12):1959–70.
72. Grantham-McGregor S, Cheung YB, Cueto S, Glewwe P, Richter L, Strupp B, et al. Developmental potential in the first 5 years for children in developing countries. *Lancet.* 2007;369(9555):60–70.
73. Chiriboga CA, Fleishman S, Champion S, Gaye-Robinson L, Abrams EJ. Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART). *J Pediatr.* 2005;146(3):402–7.
74. Shanbhag MC, Rutstein RM, Zaoutis T, Zhao H, Chao D, Radcliffe J. Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy. *Arch Pediatr Adolesc Med.* 2005;159(7):651–6.
75. Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR, 3rd, et al. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. *AIDS.* 2009;23(14):1893–901.
76. Ettenhofer ML, Foley J, Castellon SA, Hinkin CH. Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS. *Neurology.* 2010;74(15):1217–22.
77. Malee K, Williams PL, Montepiedra G, Nichols S, Sirois PA, Storm D, et al. The role of cognitive functioning in medication adherence of children and adolescents with HIV infection. *J Pediatr Psychol.* 2009;34(2):164–75.
78. Parameswaran Y, Garvey LJ, Ashby J, Foster CJ, Fidler S, Winston A. High rates of asymptomatic neurocognitive impairment in vertically acquired HIV-1-infected adolescents surviving to adulthood. *J Acquir Immune Defic Syndr.* 2010;55(1):134–6.
79. Ruel TD, Boivin MJ, Boal HE, Bangirana P, Charlebois E, Havlir DV, et al. Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. *Clin Infect Dis.* 2012;54(7):1001–9.
80. Bagenda D, Nassali A, Kalyesubula I, Sherman B, Drotar D, Boivin MJ, et al. Health, neurologic, and cognitive status of HIV-infected, long-surviving, and antiretroviral-naïve Ugandan children. *Pediatrics.* 2006;117(3):729–40.
81. Laughton B, Cornell M, Boivin M, Van Rie A. Neurodevelopment in perinatally HIV-infected children: a concern for adolescence. *J Int AIDS Soc.* 2013;16:18603, doi: <http://dx.doi.org/10.7448/IAS.16.1.18603>
82. Cysique LA, Waters EK, Brew BJ. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. *BMC Neurol.* 2011;11:148.
83. Eisfeld C, Reichelt D, Evers S, Hustedt I. CSF penetration by antiretroviral drugs. *CNS Drugs.* 2013;27(1):31–55.
84. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. *J Neurovirol.* 2011;17(1):3–16.
85. Tamula MA, Wolters PL, Walsek C, Zeichner S, Civitello L. Cognitive decline with immunologic and virologic stability in four children with human immunodeficiency virus disease. *Pediatrics.* 2003;112(3 Pt 1):679–84.
86. Crowell CS, Malee KM, Yogev R, Muller WJ. Neurologic disease in HIV-infected children and the impact of combination antiretroviral therapy. *Rev Med Virol.* 2014;24(5):316–31.
87. Blanchette N, Smith ML, King S, Fernandes-Penney A, Read S. Cognitive development in school-age children with vertically transmitted HIV infection. *Dev Neuropsychol.* 2002;21(3):223–41.
88. Foster CJ, Biggs RL, Melvin D, Walters MD, Tudor-Williams G, Lyall EG. Neurodevelopmental outcomes in children with HIV infection under 3 years of age. *Dev Med Child Neurol.* 2006;48(8):677–82.
89. Jeremy RJ, Kim S, Nozyce M, Nachman S, McIntosh K, Pelton SI, et al. Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. *Pediatrics.* 2005;115(2):380–7.
90. Koekkoek S, de Sonnevill LM, Wolfs TF, Licht R, Geelen SP. Neurocognitive function profile in HIV-infected school-age children. *Eur J Paediatr Neurol.* 2008;12(4):290–7.
91. Lindsey JC, Malee KM, Brouwers P, Hughes MD, PACTG 219C Study Team. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy. *Pediatrics.* 2007;119(3):e681–93.
92. Nozyce ML, Lee SS, Wiznia A, Nachman S, Mofenson LM, Smith ME, et al. A behavioral and cognitive profile of clinically stable HIV-infected children. *Pediatrics.* 2006;117(3):763–70.

93. van Arnhem LA, Bunders MJ, Scherpbier HJ, Majoie CB, Reneman L, Frinking O, et al. Neurologic abnormalities in HIV-1 infected children in the era of combination antiretroviral therapy. *PLoS One*. 2013;8(5):e64398.
94. Walker SY, Pierre RB, Christie CD, Chang SM. Neurocognitive function in HIV-positive children in a developing country. *Int J Infect Dis*. 2013;17(10):e862–7.
95. Cohen S, Ter Stege JA, Geurtsen GJ, Scherpbier HJ, Kuijpers TW, Reiss P, et al. Poorer cognitive performance in perinatally HIV-infected children versus healthy socioeconomically matched controls. *Clin Infect Dis*. 2015;60(7):1111–9.
96. Laughton B, Cornell M, Grove D, Kidd M, Springer PE, Dobbels E, et al. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. *AIDS*. 2012;26(13):1685–90.
97. Crowell CS, Huo Y, Tassiopoulos K, Malee KM, Yogev R, Hazra R, et al. Early viral suppression improves neurocognitive outcomes in HIV-infected children. *AIDS*. 2015;29(3):295–304.
98. Puthanakit T, Ananworanich J, Vonthanak S, Kosalaraksa P, Hansudewechakul R, van der Lugt J, et al. Cognitive function and neurodevelopmental outcomes in HIV-infected children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study. *Pediatr Infect Dis J*. 2013;32(5):501–8.
99. Puthanakit T, Saphonn V, Ananworanich J, Kosalaraksa P, Hansudewechakul R, Vibol U, et al. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. *Lancet Infect Dis*. 2012;12(12):933–41.
100. Pratt RD, Nichols S, McKinney N, Kwok S, Dankner WM, Spector SA. Virologic markers of human immunodeficiency virus type 1 in cerebrospinal fluid of infected children. *J Infect Dis*. 1996;174(2):288–93.
101. Sei S, Stewart SK, Farley M, Mueller BU, Lane JR, Robb ML, et al. Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy. *J Infect Dis*. 1996;174(6):1200–6.
102. Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. *Neurology*. 2009;73(5):342–8.
103. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. *AIDS*. 2011;25(3):357–65.
104. Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. *J Acquir Immune Defic Syndr*. 2009;52(1):56–63.
105. Garvey L, Surendrakumar V, Winston A. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. *HIV Clin Trials*. 2011;12(6):333–8.
106. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. *AIDS*. 2009;23(11):1359–66.
107. Grody WW, Cheng L, Lewis W. Infection of the heart by the human immunodeficiency virus. *Am J Cardiol*. 1990;66(2):203–6.
108. Lipshultz SE, Chanock S, Sanders SP, Colan SD, Perez-Atayde A, McIntosh K. Cardiovascular manifestations of human immunodeficiency virus infection in infants and children. *Am J Cardiol*. 1989;63(20):1489–97.
109. McDonald LA, Kaltman JR. Cardiovascular disease in adult and pediatric HIV/AIDS. *J Am Coll Cardiol*. 2009;54(13):1185–8.
110. Calabrese LH, Proffitt MR, Yen-Lieberman B, Hobbs RE, Ratliff NB. Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium. *Ann Intern Med*. 1987;107(5):691–2.
111. Lipshultz SE, Fox CH, Perez-Atayde AR, Sanders SP, Colan SD, McIntosh K, et al. Identification of human immunodeficiency virus-1 RNA and DNA in the heart of a child with cardiovascular abnormalities and congenital acquired immune deficiency syndrome. *Am J Cardiol*. 1990;66(2):246–50.
112. Fiala M, Popik W, Qiao JH, Lossinsky AS, Alce T, Tran K, et al. HIV-1 induces cardiomyopathy by cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signaling. *Cardiovasc Toxicol*. 2004;4(2):97–107.
113. Monsuez JJ, Escaut L, Teicher E, Charniot JC, Vittecoq D. Cytokines in HIV-associated cardiomyopathy. *Int J Cardiol*. 2007;120(2):150–7.
114. Satoh M, Minami Y, Takahashi Y, Nakamura M. Immune modulation: role of the inflammatory cytokine cascade in the failing human heart. *Curr Heart Fail Rep*. 2008;5(2):69–74.
115. Lewis W. Cardiomyopathy in AIDS: a pathophysiological perspective. *Prog Cardiovasc Dis*. 2000;43(2):151–70.
116. Lewis W. Mitochondrial DNA replication, nucleoside reverse-transcriptase inhibitors, and AIDS cardiomyopathy. *Prog Cardiovasc Dis*. 2003;45(4):305–18.
117. Lewis W, Papoian T, Gonzalez B, Louie H, Kelly DP, Payne RM, et al. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts. *Lab Invest*. 1991;65(2):228–36.
118. Benbrik E, Chariot P, Bonavaud S, Ammi-Said M, Frisdal E, Rey C, et al. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddi) and zalcitabine (ddC) on cultured human muscle cells. *J Neurol Sci*. 1997;149(1):19–25.
119. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. *Antimicrob Agents Chemother*. 2002;46(3):716–23.
120. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. *AIDS*. 1998;12(14):1735–44.
121. Medina DJ, Tsai CH, Hsiung GD, Cheng YC. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. *Antimicrob Agents Chemother*. 1994;38(8):1824–8.
122. Saitoh A, Fenton T, Alvero C, Fletcher CV, Spector SA. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. *Antimicrob Agents Chemother*. 2007;51(12):4236–42.
123. The pediatric pulmonary and cardiovascular complications of vertically transmitted human immunodeficiency virus (P2C2 HIV) infection study: design and methods. The P2C2 HIV Study Group. *J Clin Epidemiol*. 1996;49(11):1285–94.
124. Starc TJ, Lipshultz SE, Easley KA, Kaplan S, Bricker JT, Colan SD, et al. Incidence of cardiac abnormalities in children with human immunodeficiency virus infection: the prospective P2C2 HIV study. *J Pediatr*. 2002;141(3):327–34.
125. Patel K, Van Dyke RB, Mittleman MA, Colan SD, Oleske JM, Seage GR, 3rd, et al. The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1. *AIDS*. 2012;26(16):2027–37.
126. Lipshultz SE, Williams PL, Wilkinson JD, Leister EC, Van Dyke RB, Shearer WT, et al. Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study. *JAMA Pediatr*. 2013;167(6):520–7.
127. Lipshultz SE, Shearer WT, Thompson B, Rich KC, Cheng I, Orav EJ, et al. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study). *J Am Coll Cardiol*. 2011;57(1):76–85.
128. Williams PL, Crain MJ, Yildirim C, Hazra R, Van Dyke RB, Rich K, et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. *JAMA Pediatr*. 2015;169(1):48–55.
129. Brown SC, Schoeman CJ, Bester CJ. Cardiac findings in children admitted to a hospital general ward in South Africa: a comparison of HIV-infected and uninfected children. *Cardiovasc J S Afr*. 2005;16(4):206–10.
130. Lubega S, Zirembuzi GW, Lwabi P. Heart disease among children with HIV/AIDS attending the paediatric infectious disease clinic at Mulago Hospital. *Afr Health Sci*. 2005;5(3):219–26.
131. Okoromah CA, Ojo OO, Ogunkunle OO. Cardiovascular dysfunction in HIV-infected children in a sub-Saharan African country: comparative cross-sectional observational study. *J Trop Pediatr*. 2012;58(1):3–11.
132. Lai W, Mertens L, Cohen M, Geva T. Echocardiography in pediatric and congenital heart disease. London: Wiley-Blackwell; 2009.
133. Sims A, Frank L, Cross R, Clauss S, Dimock D, Purdy J, et al. Abnormal cardiac strain in children and young adults with HIV acquired in early life. *J Am Soc Echocardiogr*. 2012;25(7):741–8.
134. Price JC, Thio CL. Liver disease in the HIV-infected individual. *Clin Gastroenterol Hepatol*. 2010;8(12):1002–12.
135. Siberry GK, Cohen RA, Harris DR, Cruz ML, Oliveira R, Peixoto MF, et al. Prevalence and predictors of elevated aspartate aminotransferase-to-platelet ratio index in Latin American perinatally HIV-infected children. *Pediatr Infect Dis J*. 2014;33(2):177–82.
136. Siberry GK, Patel K, Pinto JA, Puga A, Mirza A, Miller TL, et al. Elevated aspartate aminotransferase-to-platelet ratio index in perinatally HIV-infected children in the United States. *Pediatr Infect Dis J*. 2014;33(8):855–7.

137. Bamford A, Turkova A, Lyall H, Foster C, Klein N, Bastiaans D, et al. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life. *HIV Med.* 2015. doi: <http://dx.doi.org/10.1111/hiv.12217>. [Epub ahead of print].
138. Rubio A, Monpoux F, Huguon E, Truchi R, Triolo V, Rosenthal-Allieri MA, et al. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children. *J Pediatr Gastroenterol Nutr.* 2009;49(5):599–606.
139. Martinez-Sierra C, Arizcorreta A, Diaz F, Roldan R, Martin-Herrera L, Perez-Guzman E, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfecting with hepatitis C virus and human immunodeficiency virus. *Clin Infect Dis.* 2003;36(4):491–8.
140. England K, Thorne C, Newell ML. Vertically acquired paediatric coinfection with HIV and hepatitis C virus. *Lancet Infect Dis.* 2006;6(2):83–90.
141. Abera B, Zenebe Y, Mulu W, Kibret M, Kahsu G. Seroprevalence of hepatitis B and C viruses and risk factors in HIV infected children at the Felgehiwot referral hospital, Ethiopia. *BMC Res Notes.* 2014;7:838.
142. Toussi SS, Abadi J, Rosenberg M, Levanon D. Prevalence of hepatitis B and C virus infections in children infected with HIV. *Clin Infect Dis.* 2007;45(6):795–8.
143. Zhou S, Zhao Y, He Y, Li H, Bulterys M, Sun X, et al. Hepatitis B and hepatitis C seroprevalence in children receiving antiretroviral therapy for human immunodeficiency virus-1 infection in China, 2005–2009. *J Acquir Immune Defic Syndr.* 2010;54(2):191–6.
144. Healy SA, Gupta S, Melvin AJ. HIV/HBV coinfection in children and antiviral therapy. *Expert Rev Anti Infect Ther.* 2013;11(3):251–63.
145. Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Handelsman E, et al. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. *Pediatr Infect Dis J.* 2013;32(Suppl 2):i-KK4.
146. Bhimma R, Purswani MU, Kala U. Kidney disease in children and adolescents with perinatal HIV-1 infection. *J Int AIDS Soc.* 2013;16:18596. doi: <http://dx.doi.org/10.7448/IAS.16.1.18596>
147. Lescure FX, Plateau C, Pacanowski J, Brocheriou I, Rondeau E, Girard PM, et al. HIV-associated kidney glomerular diseases: changes with time and HAART. *Nephrol Dial Transplant.* 2012;27(6):2349–55.
148. Ray PE. Taking a hard look at the pathogenesis of childhood HIV-associated nephropathy. *Pediatr Nephrol.* 2009;24(11):2109–19.
149. Wyatt CM, Meliambro K, Klotman PE. Recent progress in HIV-associated nephropathy. *Ann Rev Med.* 2012;63:147–59.
150. Mitchell CD, Chernoff MC, Seage GR, 3rd, Purswani MU, Spiegel HM, Zilleruelo G, et al. Predictors of resolution and persistence of renal laboratory abnormalities in pediatric HIV infection. *Pediatr Nephrol.* 2015;30(1):153–65.
151. Della Negra M, de Carvalho AP, de Aquino MZ, da Silva MT, Pinto J, White K, et al. A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents. *Pediatr Infect Dis J.* 2012;31(5):469–73.
152. Pontrelli G, Cotugno N, Amodio D, Zangari P, Tchidjou HK, Baldassari S, et al. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors. *BMC Infect Dis.* 2012;12:18.
153. Purswani M, Patel K, Kopp JB, Seage GR 3rd, Chernoff MC, Hazra R, et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection. *Pediatr Infect Dis J.* 2013;32(5):495–500.
154. Viganò A, Bedogni G, Manfredini V, Giacomet V, Cerini C, di Nello F, et al. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. *Clin Drug Investig.* 2011;31(6):407–15.
155. Ramsuran D, Bhimma R, Ramdial PK, Naicker E, Adhikari M, Deonarain J, et al. The spectrum of HIV-related nephropathy in children. *Pediatr Nephrol.* 2012;27(5):821–7.
156. Bostrom MA, Freedman BI. The spectrum of MYH9-associated nephropathy. *Clin J Am Soc Nephrol.* 2010;5(6):1107–13.
157. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. *J Am Soc Nephrol.* 2011;22(11):2129–37.
158. Fabian J, Naicker S. HIV and kidney disease in sub-Saharan Africa. *Nat Rev Nephrol.* 2009;5(10):591–8.
159. Purswani MU, Chernoff MC, Mitchell CD, Seage GR, 3rd, Zilleruelo G, Abitbol C, et al. Chronic kidney disease associated with perinatal HIV infection in children and adolescents. *Pediatr Nephrol.* 2012;27(6):981–9.
160. Chaparro AI, Mitchell CD, Abitbol CL, Wilkinson JD, Baldarrago G, Lopez E, et al. Proteinuria in children infected with the human immunodeficiency virus. *J Pediatr.* 2008;152(6):844–9.
161. Andiman WA, Chernoff MC, Mitchell C, Purswani M, Oleske J, Williams PL, et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. *Pediatr Infect Dis J.* 2009;28(7):619–25.
162. Turret J, Tostivint I, du Montcel ST, Bragg-Gresham J, Karie S, Vigneau C, et al. Outcome and prognosis factors in HIV-infected hemodialysis patients. *Clin J Am Soc Nephrol.* 2006;1(6):1241–7.
163. Gordillo R, Del Rio M, Woroniecki RP. Dialysis-associated morbidity, ultrafiltration, and cardiovascular variables in children with HIV infection. *Clin Nephrol.* 2011;75(5):434–9.
164. Gruber SA, Doshi MD, Cincotta E, Brown KL, Singh A, Morawski K, et al. Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates. *Transplantation.* 2008;86(2):269–74.
165. Kumar MS, Sierka DR, Damask AM, Fyfe B, McAlack RF, Heifets M, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. *Kidney Int.* 2005;67(4):1622–9.
166. Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. *Transplantation.* 2003;75(4):425–9.
167. Kreuzer KA, Rockstroh JK. Pathogenesis and pathophysiology of anemia in HIV infection. *Ann Hematol.* 1997;75(5–6):179–87.
168. Wiener LS, Kohrt BA, Battles HB, Pao M. The HIV experience: youth identified barriers for transitioning from pediatric to adult care. *J Pediatr Psychol.* 2011;36(2):141–54.
169. Biggar RJ, Rabkin CS. The epidemiology of AIDS – related neoplasms. *Hematol Oncol Clin North Am.* 1996;10(5):997–1010.
170. Brent AJ, Oundo JO, Mwangi I, Ochola L, Lowe B, Berkley JA. Salmonella bacteremia in Kenyan children. *Pediatr Infect Dis J.* 2006;25(3):230–6.
171. Graham SM, Walsh AL, Molyneux EM, Phiri AJ, Molyneux ME. Clinical presentation of non-typhoidal Salmonella bacteraemia in Malawian children. *Trans R Soc Trop Med Hyg.* 2000;94(3):310–4.
172. Sirisanthana V, Sirisanthana T. Disseminated *Penicillium marneffei* infection in human immunodeficiency virus-infected children. *Pediatr Infect Dis J.* 1995;14(11):935–40.
173. Clark TD, Mmiro F, Ndugwa C, Perry RT, Jackson JB, Melikian G, et al. Risk factors and cumulative incidence of anaemia among human immunodeficiency virus-infected children in Uganda. *Ann Trop Paediatr.* 2002;22(1):11–7.
174. Hoyt L, Oleske J, Holland B, Connor E. Nontuberculous mycobacteria in children with acquired immunodeficiency syndrome. *Pediatr Infect Dis J.* 1992;11(5):354–60.
175. Otieno RO, Ouma C, Ong'echa JM, Keller CC, Were T, Waindi EN, et al. Increased severe anemia in HIV-1-exposed and HIV-1-positive infants and children during acute malaria. *AIDS.* 2006;20(2):275–80.
176. van Eijk AM, Ayisi JG, Ter Kuile FO, Misore AO, Otieno JA, Kolczak MS, et al. Malaria and human immunodeficiency virus infection as risk factors for anemia in infants in Kisumu, western Kenya. *Am J Trop Med Hyg.* 2002;67(1):44–53.
177. Capparelli EV, Englund JA, Connor JD, Spector SA, McKinney RE, Palumbo P, et al. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. *J Clin Pharmacol.* 2003;43(2):133–40.
178. Englund JA, Baker CJ, Raskino C, McKinney RE, Petrie B, Fowler MG, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. *N Engl J Med.* 1997;336(24):1704–12.
179. Sperling RS, Shapiro DE, McSherry GD, Britto P, Cunningham BE, Culnane M, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. *AIDS.* 1998;12(14):1805–13.
180. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. *N Engl J Med.* 1994;331(18):1173–80.
181. Dryden-Peterson S, Shapiro RL, Hughes MD, Powis K, Ogwu A, Moffat C, et al. Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. *J Acquir Immune Defic Syndr.* 2011;56(5):428–36.

182. Calis JC, van Hensbroek MB, de Haan RJ, Moons P, Brabin BJ, Bates I. HIV-associated anemia in children: a systematic review from a global perspective. *AIDS*. 2008;22(10):1099–112.
183. Marti-Carvajal AJ, Sola I, Pena-Martí GE, Comunian-Carrasco G. Treatment for anemia in people with AIDS. *Cochrane Database Syst Rev*. 2011;(10):CD004776.
184. Leonard EG, McComsey GA. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival. *Infect Dis Clin North Am*. 2005;19(3):713–29.
185. McComsey GA, Leonard E. Metabolic complications of HIV therapy in children. *AIDS*. 2004;18(13):1753–68.
186. Aldrovandi GM, Lindsey JC, Jacobson DL, Zadilka A, Sheeran E, Moya J, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. *AIDS*. 2009;23(6):661–72.
187. Wohl DA, Brown TT. Management of morphologic changes associated with antiretroviral use in HIV-infected patients. *J Acquir Immune Defic Syndr*. 2008;49(Suppl 2):S93–S100.
188. Barbaro G. Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome. *Curr Pharm Des*. 2007;13(21):2208–13.
189. Zanone Poma B, Riva A, Nasi M, Cicconi P, Brogini V, Lepri AC, et al. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. *AIDS*. 2008;22(14):1769–78.
190. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. *Pediatr Infect Dis J*. 2002;21(5):405–10.
191. Babl FE, Regan AM, Pelton SI. Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals. *Lancet*. 1999;353(9160):1243–4.
192. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. *AIDS*. 2004;18(10):1443–51.
193. Kinabo GD, Sprengers M, Msuya LJ, Shayo AM, van Asten H, Dolmans WM, et al. Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy. *Pediatr Infect Dis J*. 2013;32(1):39–44.
194. Piloya T, Bakeera-Kitaka S, Kekitiinwa A, Kanya MR. Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study. *J Int AIDS Soc*. 2012;15(2):17427, doi: <http://dx.doi.org/10.7448/IAS.15.2.17427>
195. Sanchez Torres AM, Munoz Muniz R, Madero R, Borque C, Garcia-Miguel MJ, De Jose Gomez MI. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. *Eur J Pediatr*. 2005;164(5):271–6.
196. Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV, et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. *Pediatrics*. 2004;114(2):e235–42.
197. Alam N, Cortina-Borja M, Goetghebuer T, Marczyńska M, Vignano A, Thorne C, et al. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors. *J Acquir Immune Defic Syndr*. 2012;59(3):314–24.
198. Dapena M, Jimenez B, Noguera-Julian A, Soler-Palacin P, Fortuny C, Lahoz R, et al. Metabolic disorders in vertically HIV-infected children: future adults at risk for cardiovascular disease. *J Pediatr Endocrinol Metab*. 2012;25(5–6):529–35.
199. Aupibul L, Puthanakit T, Lee B, Mangklabruks A, Sirisanthana T, Sirisanthana V. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. *Antivir Ther*. 2007;12(8):1247–54.
200. Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. *Pediatrics*. 2002;110(5):e56.
201. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. *Pediatr Infect Dis J*. 2003;22(1):77–84.
202. Ammassari A, Antinori A, Cozzi-Lepri A, Trotta MP, Nasti G, Ridolfo AL, et al. Relationship between HAART adherence and adipose tissue alterations. *J Acquir Immune Defic Syndr*. 2002;31(Suppl 3):S140–4.
203. Holzemer WL, Uys L, Makoe L, Stewart A, Phetlhu R, Dlamini PS, et al. A conceptual model of HIV/AIDS stigma from five African countries. *J Adv Nurs*. 2007;58(6):541–51.
204. Makoe LN, Portillo CJ, Uys LR, Dlamini PS, Greeff M, Chirwa M, et al. The impact of taking or not taking ARVs on HIV stigma as reported by persons living with HIV infection in five African countries. *AIDS Care*. 2009;21(11):1357–62.
205. Mutimura E, Stewart A, Crowther NJ. Assessment of quality of life in HAART-treated HIV-positive subjects with body fat redistribution in Rwanda. *AIDS Res Ther*. 2007;4:19.
206. Miller TL, Orav EJ, Lipshultz SE, Arheart KL, Duggan C, Weinberg GA, et al. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. *J Pediatr*. 2008;153(4):491–7.
207. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. *AIDS*. 1998;12(7):F51–8.
208. Beregszaszi M, Dollfus C, Levine M, Faye A, Deghmoun S, Bellal N, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. *J Acquir Immune Defic Syndr*. 2005;40(2):161–8.
209. Rosso R, Parodi A, d'Annunzio G, Ginocchio F, Nicolini L, Torrisi C, et al. Evaluation of insulin resistance in a cohort of HIV-infected youth. *Eur J Endocrinol*. 2007;157(5):655–9.
210. Carter RJ, Wiener J, Abrams EJ, Farley J, Nesheim S, Palumbo P, et al. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999–2004: a longitudinal analysis. *J Acquir Immune Defic Syndr*. 2006;41(4):453–60.
211. Chantry CJ, Hughes MD, Alvero C, Cervia JS, Meyer WA, 3rd, Hodge J, et al. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. *Pediatrics*. 2008;122(1):e129–38.
212. Kim JY, Zautis T, Chu J, Zhao H, Rutstein R. Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1 infected children: a retrospective cohort study. *Pharmacoepidemiol Drug Saf*. 2009;18(7):589–94.
213. Tassiopoulos K, Williams PL, Seage GR, 3rd, Crain M, Oleske J, Farley J, et al. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. *J Acquir Immune Defic Syndr*. 2008;47(5):607–14.
214. Jacobson DL, Williams P, Tassiopoulos K, Melvin A, Hazra R, Farley J. Clinical management and follow-up of hypercholesterolemia among perinatally HIV-infected children enrolled in the PACTG 219C study. *J Acquir Immune Defic Syndr*. 2011;57(5):413–20.
215. Gonzalez-Tome MI, Amador JT, Pena MJ, Gomez ML, Conejo PR, Fontelos PM. Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. *BMC Infect Dis*. 2008;8:144.
216. McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A, First Pediatric Switch Study. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. *Pediatrics*. 2003;111(3):e275–81.
217. Strehlau R, Coovadia A, Abrams EJ, Martens L, Arpadi S, Meyers T, et al. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2012;60(4):369–76.
218. Vignano A, Zuccotti GV, Puzzovio M, Pivetti V, Zamproni I, Cerini C, et al. Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths. *Antivir Ther*. 2010;15(7):1053–8.
219. Daniels SR, Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in childhood. *Pediatrics*. 2008;122(1):198–208.
220. Ten S, Maclaren N. Insulin resistance syndrome in children. *J Clin Endocrinol Metab*. 2004;89(6):2526–39.
221. Alves C, Oliveira AC, Brites C. Lipodystrophic syndrome in children and adolescents infected with the human immunodeficiency virus. *Braz J Infect Dis*. 2008;12(4):342–8.
222. Bockhorst JL, Kseiry I, Toye M, Chipkin SR, Stechenberg BW, Fisher DJ, et al. Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. *Pediatr Infect Dis J*. 2003;22(5):463–5.
223. Aboud M, Elgalib A, Kulasegaram R, Peters B. Insulin resistance and HIV infection: a review. *Int J Clin Pract*. 2007;61(3):463–72.
224. Wierzbicki AS, Purdon SD, Hardman TC, Kulasegaram R, Peters BS. HIV lipodystrophy and its metabolic consequences: implications for clinical practice. *Curr Med Res Opin*. 2008;24(3):609–24.
225. Young F, Critchley JA, Johnstone LK, Unwin NC. A review of co-morbidity between infectious and chronic disease in sub Saharan Africa: TB and diabetes mellitus, HIV and metabolic syndrome, and the impact of globalization. *Global Health*. 2009;5:9.
226. Hazra R, Hance LF, Monteiro JP, Ruz NP, Machado DM, Saavedra M, et al. Insulin resistance and glucose and lipid concentrations in a cohort of perinatally HIV-infected Latin American children. *Pediatr Infect Dis J*. 2013;32(7):757–9.

227. Lee B, Aupibul L, Sirisanthana V, Mangklabruks A, Sirisanthana T, Puthanakit T. Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand. *HIV Med.* 2009;10(2):72–8.
228. Geffner ME, Patel K, Miller TL, Hazra R, Silio M, Van Dyke RB, et al. Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study. *Horm Res Paediatr.* 2011;76(6):386–91.
229. Viganò A, Brambilla P, Cafarelli L, Giacomet V, Borgonovo S, Zamproni I, et al. Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz. *Antivir Ther.* 2007;12(3):297–302.
230. Viganò A, Brambilla P, Pattarino G, Stucchi S, Fasan S, Raimondi C, et al. Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children: a longitudinal, observational cohort study. *Clin Drug Investig.* 2009;29(2):101–9.
231. Viganò A, Cerini C, Pattarino G, Fasan S, Zuccotti GV. Metabolic complications associated with antiretroviral therapy in HIV-infected and HIV-exposed uninfected paediatric patients. *Expert Opin Drug Saf.* 2010;9(3):431–45.
232. Barlow-Mosha L, Eckard AR, McComsey GA, Musoke PM. Metabolic complications and treatment of perinatally HIV-infected children and adolescents. *J Int AIDS Soc.* 2013;16:18600, doi: <http://dx.doi.org/10.7448/IAS.16.1.18600>
233. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. *Clin Infect Dis.* 2001;32(1):130–9.
234. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med.* 2003;349(21):1993–2003.
235. Stagi S, Bindi G, Galluzzi F, Galli L, Salti R, de Martino M. Changed bone status in human immunodeficiency virus type 1 (HIV-1) perinatally infected children is related to low serum free IGF-I. *Clin Endocrinol.* 2004;61(6):692–9.
236. Zamboni G, Antoniazzi F, Bertoldo F, Lauriola S, Antozzi L, Tato L. Altered bone metabolism in children infected with human immunodeficiency virus. *Acta Paediatr.* 2003;92(1):12–6.
237. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Viganò A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. *AIDS.* 2001;15(14):1823–9.
238. Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Viganò A. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. *J Clin Endocrinol Metab.* 2004;89(1):24–8.
239. Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. *Pediatrics.* 2005;116(6):e846–54.
240. Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. *Pediatrics.* 2006;118(3):e711–8.
241. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. *J Pediatr.* 2008;152(4):582–4.
242. Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Viganò A. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. *J Acquir Immune Defic Syndr.* 2005;40(4):448–50.
243. Viganò A, Aldrovandi GM, Giacomet V, Merlo M, Martelli L, Beretta S, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. *Antivir Ther.* 2005;10(8):917–24.
244. Giacomet V, Nannini P, Viganò A, Erba P, Benincaso A, Bedogni G, et al. Long-term renal effects of tenofovir-disoproxil-fumarate in vertically HIV-infected children, adolescents, and young adults: a 132-month follow-up study. *Clin Drug Investig.* 2015;35(7):419–26.
245. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. *JAMA.* 2004;292(2):191–201.
246. Thomas V, Purdy JB, Reynolds JC, Hadigan C, Hazra R. Bone mineral density in adolescents infected with HIV perinatally or childhood: data from the NIH Intramural Program. 16th Conference on Retroviruses and Opportunistic Infections (CROI); February 8–11; Montreal, Canada; 2009.
247. Puthanakit T, Siberry GK. Bone health in children and adolescents with perinatal HIV infection. *J Int AIDS Soc.* 2013;16:18575, doi: <http://dx.doi.org/10.7448/IAS.16.1.18575>
248. Buve A, Jespers V, Crucitti T, Fichorova RN. The vaginal microbiota and susceptibility to HIV. *AIDS.* 2014;28(16):2333–44.
249. Cone RA. Vaginal microbiota and sexually transmitted infections that may influence transmission of cell-associated HIV. *J Infect Dis.* 2014;210(Suppl 3):S616–21.
250. Venkatesh KK, van der Straten A, Mayer KH, Blanchard K, Ramjee G, Lurie MN, et al. African women recently infected with HIV-1 and HSV-2 have increased risk of acquiring *Neisseria gonorrhoeae* and *Chlamydia trachomatis* in the methods for improving reproductive health in Africa trial. *Sex Transm Dis.* 2011;38(6):562–70.
251. Marschalko M, Ponyai K, Karpati S. [Sexually transmitted coinfections. HIV coinfections]. *Orv Hetil.* 2015;156(1):4–9.
252. Belongia EA, Danila RN, Angamuthu V, Hickman CD, DeBoer JM, MacDonald KL, et al. A population-based study of sexually transmitted disease incidence and risk factors in human immunodeficiency virus-infected people. *Sex Transm Dis.* 1997;24(5):251–6.
253. Hankins C, Coutlee F, Lapointe N, Simard P, Tran T, Samson J, et al. Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women's HIV Study Group. *CMAJ.* 1999;160(2):185–91.
254. Maiman M, Fruchter RG, Serur E, Remy JC, Feuer G, Boyce J. Human immunodeficiency virus infection and cervical neoplasia. *Gynecol Oncol.* 1990;38(3):377–82.
255. Moscicki AB, Ellenberg JH, Vermund SH, Holland CA, Darragh T, Crowley-Nowick PA, et al. Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. *Arch Pediatr Adolesc Med.* 2000;154(2):127–34.
256. Mullins TL, Rudy BJ, Wilson CM, Sucharew H, Kahn JA. Incidence of sexually transmitted infections in HIV-infected and HIV-uninfected adolescents in the USA. *Int J STD AIDS.* 2013;24(2):123–7.
257. Brogly SB, Watts DH, Ylitalo N, Franco EL, Seage GR, 3rd, Oleske J, et al. Reproductive health of adolescent girls perinatally infected with HIV. *Am J Public Health.* 2007;97(6):1047–52.
258. Agwu AL, Jang SS, Korthuis PT, Araneta MR, Gebo KA. Pregnancy incidence and outcomes in vertically and behaviorally HIV-infected youth. *JAMA.* 2011;305(5):468–70.
259. Jao J, Agwu A, Mhango G, Kim A, Park K, Posada R, et al. Growth patterns in the first year of life differ in infants born to perinatally vs. nonperinatally HIV-infected women. *AIDS.* 2015;29(1):111–6.
260. Kennedy CE, Spaulding AB, Brickley DB, Almers L, Mirjahangir J, Packel L, et al. Linking sexual and reproductive health and HIV interventions: a systematic review. *J Int AIDS Soc.* 2010;13:26.
261. Davis AM, Brown RF, Taylor JL, Epstein RA, McPheeters ML. Transition care for children with special health care needs. *Pediatrics.* 2014;134(5):900–8.
262. Dowshen N, D'Angelo L. Health care transition for youth living with HIV/AIDS. *Pediatrics.* 2011;128(4):762–71.
263. Mellins CA, Brackis-Cott E, Leu CS, Elkington KS, Dolezal C, Wiznia A, et al. Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters. *J Child Psychol Psychiatry.* 2009;50(9):1131–8.
264. Gaughan DM, Hughes MD, Oleske JM, Malee K, Gore CA, Nachman S, et al. Psychiatric hospitalizations among children and youths with human immunodeficiency virus infection. *Pediatrics.* 2004;113(6):e544–51.
265. Scharko AM. DSM psychiatric disorders in the context of pediatric HIV/AIDS. *AIDS Care.* 2006;18(5):441–5.
266. Benton TD. Psychiatric considerations in children and adolescents with HIV/AIDS. *Pediatr Clin North Am.* 2011;58(4):989–1002, xii.
267. Mellins CA, Malee KM. Understanding the mental health of youth living with perinatal HIV infection: lessons learned and current challenges. *J Int AIDS Soc.* 2013;16:18593, doi: <http://dx.doi.org/10.7448/IAS.16.1.18593>
268. Chernoff M, Nachman S, Williams P, Brouwers P, Heston J, Hodge J, et al. Mental health treatment patterns in perinatally HIV-infected youth and controls. *Pediatrics.* 2009;124(2):627–36.
269. Gadow KD, Chernoff M, Williams PL, Brouwers P, Morse E, Heston J, et al. Co-occurring psychiatric symptoms in children perinatally infected with HIV and peer comparison sample. *J Dev Behav Pediatr.* 2010;31(2):116–28.

270. Mellins CA, Elkington KS, Leu CS, Santamaria EK, Dolezal C, Wiznia A, et al. Prevalence and change in psychiatric disorders among perinatally HIV-infected and HIV-exposed youth. *AIDS Care*. 2012;24(8):953–62.
271. Malee KM, Tassiopoulos K, Huo Y, Siberry G, Williams PL, Hazra R, et al. Mental health functioning among children and adolescents with perinatal HIV infection and perinatal HIV exposure. *AIDS Care*. 2011;23(12):1533–44.
272. Nachman S, Chernoff M, Williams P, Hodge J, Heston J, Gadow KD. Human immunodeficiency virus disease severity, psychiatric symptoms, and functional outcomes in perinatally infected youth. *Arch Pediatr Adolesc Med*. 2012; 166(6):528–35.
273. Wood SM, Shah SS, Steenhoff AP, Rutstein RM. The impact of AIDS diagnoses on long-term neurocognitive and psychiatric outcomes of surviving adolescents with perinatally acquired HIV. *AIDS*. 2009;23(14):1859–65.
274. Bomba M, Nacinovich R, Oggiano S, Cassani M, Baushi L, Bertulli C, et al. Poor health-related quality of life and abnormal psychosocial adjustment in Italian children with perinatal HIV infection receiving highly active antiretroviral treatment. *AIDS Care*. 2010;22(7):858–65.
275. Gadow KD, Angelidou K, Chernoff M, Williams PL, Heston J, Hodge J, et al. Longitudinal study of emerging mental health concerns in youth perinatally infected with HIV and peer comparisons. *J Dev Behav Pediatr*. 2012;33(6): 456–68.
276. Elkington KS, Robbins RN, Bauermeister JA, Abrams EJ, McKay M, Mellins CA. Mental health in youth infected with and affected by HIV: the role of caregiver HIV. *J Pediatr Psychol*. 2011;36(3):360–73.
277. Mellins CA, Brackis-Cott E, Dolezal C, Abrams EJ. Psychiatric disorders in youth with perinatally acquired human immunodeficiency virus infection. *Pediatr Infect Dis J*. 2006;25(5):432–7.
278. Betancourt T, Scorza P, Kanyanganzi F, Fawzi MC, Sezibera V, Cyamatare F, et al. HIV and child mental health: a case-control study in Rwanda. *Pediatrics*. 2014;134(2):e464–72.
279. Zeegers I, Rabie H, Swanevelde S, Edson C, Cotton M, van Toorn R. Attention deficit hyperactivity and oppositional defiance disorder in HIV-infected South African children. *J Trop Pediatr*. 2010;56(2):97–102.
280. Lee B, Chhabra M, Oberdorfer P. Depression among vertically HIV-infected adolescents in Northern Thailand. *J Int Assoc Physicians AIDS Care*. 2011;10(2):89–96.
281. Havens JF, Mellins CA. Psychiatric aspects of HIV/AIDS in childhood and adolescence. In: Rutter M, Taylor E, editors. *Child and adolescent psychiatry*. 5th ed. Oxford, UK: Blackwell; 2008. p. 545–55.
282. Rutter M. Children of sick parents. London: Oxford University Press; 1966.
283. Dowdney L. Childhood bereavement following parental death. *J Child Psychol Psychiatry*. 2000;41(7):819–30.
284. Tremblay GC, Israel AC. Children's adjustment to parental death. *Clin Psychol*. 1998;5:424–38.
285. Mabugu T, Revill P, van den Berg B. The methodological challenges for the estimation of quality of life in children for use in economic evaluation in low-income countries. *Value Health Reg Issues*. 2013;2:231–9.
286. Stevens M, Kirsh B, Nixon SA. Rehabilitation interventions for children living with HIV: a scoping review. *Disab Rehabil*. 2014;36(10):865–74.
287. Worthington C, Myers T, O'Brien K, Nixon S, Cockerill R. Rehabilitation in HIV/AIDS: development of an expanded conceptual framework. *AIDS Patient Care STDs*. 2005;19(4):258–71.
288. Sohn AH, Hazra R. The changing epidemiology of the global paediatric HIV epidemic: keeping track of perinatally HIV-infected adolescents. *J Int AIDS Soc*. 2013;16:18555, doi: <http://dx.doi.org/10.7448/IAS.16.1.18555>
289. Wettstein C, Mugglin C, Egger M, Blaser N, Vizcaya LS, Estill J, et al. Missed opportunities to prevent mother-to-child-transmission: systematic review and meta-analysis. *AIDS*. 2012;26(18):2361–73.
290. Ciaranello AL, Park JE, Ramirez-Avila L, Freedberg KA, Walensky RP, Leroy V. Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. *BMC Med*. 2011;9:59.
291. Mugglin C, Wandeler G, Estill J, Egger M, Bender N, Davies MA, et al. Retention in care of HIV-infected children from HIV test to start of anti-retroviral therapy: systematic review. *PLoS One*. 2013;8(2):e56446.